BioClinica Launches eHealth Cloud
NEWTOWN, PA., AUGUST 10, 2015 – BioClinica®, Inc., a specialty clinical trials services and technology provider, today announced the launch of the BioClinica eHealth Cloud™, a flexible and highly configurable platform offering that extends beyond the scope of traditional clinical trial technology approaches.
The eHealth Cloud offers unlimited accessibility and a variety of delivery options to better meet the current and future needs of both preapproval and post approval research. With public consumer, private cloud, managed cloud, and custom options, the eHealth Cloud offers the right hosting subscription model to meet the specific needs of individual clinical trials.
“The eHealth Cloud creates inherent flexibility, scalability and agility while maintaining the highest levels of quality and security,” said Mukhtar Ahmed, BioClinica’s President of eClinical Solutions. “ This represents a major leap forward in clinical trial sponsor empowerment whereby sponsors and CROs’ can choose from cloud delivery options that better enable them to achieve their scientific and business objectives.”
BioClinica’s extensive and highly interoperable clinical trials platform, that includes Express EDC, Trident RTSM, Optimizer Supply Forecasting and Simulation, OnPoint CTMS and Compass “Intelligent” Risk-Based Monitoring solution, will be optimized for delivery through the eHealth Cloud.
“The eHealth Cloud is an exciting new delivery model for BioClinica’s eClinical suite of products, providing scale, reliability, and quality of service that measures up to the most complex clinical trials” said Andrew Masters, Senior Vice President of Product Development and Technology.
Furthermore these powerful trial solutions will provide unprecedented integration capabilities though the BioClinica Cloud Transformation Gateway™, a secure standards-based integration exchange that connects BioClinica’s eClinical Platform to innovative third party applications and industry data banks.
“The BioClinica Cloud Transformation Gateway is a crucial part of the eHealth ecosystem,” said Mr. Ahmed. “There are many talented and disruptive innovators across the healthcare spectrum developing niche applications that enhance patient engagement, point of care, and scientific analytical capabilities. Our open platform approach will enable us to seamlessly and rapidly connect our core clinical trial technologies and trusted clinical data repository to these industry innovators so that that sponsors, investigator sites, and patients can benefit from their use within the clinical research setting.”
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.
